BR112019024881A2 - Agente para evitar ou tratar ataxia espinocerebelar - Google Patents

Agente para evitar ou tratar ataxia espinocerebelar Download PDF

Info

Publication number
BR112019024881A2
BR112019024881A2 BR112019024881-1A BR112019024881A BR112019024881A2 BR 112019024881 A2 BR112019024881 A2 BR 112019024881A2 BR 112019024881 A BR112019024881 A BR 112019024881A BR 112019024881 A2 BR112019024881 A2 BR 112019024881A2
Authority
BR
Brazil
Prior art keywords
spinocerebellar ataxia
agent
avoid
treat
treat spinocerebellar
Prior art date
Application number
BR112019024881-1A
Other languages
English (en)
Inventor
Kobayashi Hiroshi
Matsumoto Yoshihiko
Okuda Tomohiro
Original Assignee
Fujifilm Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co., Ltd. filed Critical Fujifilm Toyama Chemical Co., Ltd.
Publication of BR112019024881A2 publication Critical patent/BR112019024881A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção tem como objetivo proporcionar um excelente fármaco para evitar ou tratar ataxia espinocerebelar. 1-(3-(2-(1-benzotiofen-5-il)etóxi)propil)azetidin-3-ol ou um sal do mesmo tem um efeito de suprimir atrofia cerebral, especialmente atrofia cerebelar, e é útil como um agente para evitar ou tratar ataxia espinocerebelar. atrofia cerebelar observada em ataxia espinocerebelar pode ser evitada ou tratada por administrar 1-(3-(2-(1-benzotiofen-5-il)etóxi)propil) azetidin-3-ol ou um sal do mesmo.
BR112019024881-1A 2017-06-02 2018-06-01 Agente para evitar ou tratar ataxia espinocerebelar BR112019024881A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2017109885 2017-06-02
JP2017-109885 2017-06-02
JP2017128472 2017-06-30
JP2017-128472 2017-06-30
JP2017145101 2017-07-27
JP2017-145101 2017-07-27
PCT/JP2018/021224 WO2018221730A1 (ja) 2017-06-02 2018-06-01 脊髄小脳変性症予防または治療剤

Publications (1)

Publication Number Publication Date
BR112019024881A2 true BR112019024881A2 (pt) 2020-06-16

Family

ID=64454849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024881-1A BR112019024881A2 (pt) 2017-06-02 2018-06-01 Agente para evitar ou tratar ataxia espinocerebelar

Country Status (15)

Country Link
US (1) US11660287B2 (pt)
EP (1) EP3632430A4 (pt)
JP (1) JP7133547B2 (pt)
KR (1) KR20190138696A (pt)
CN (1) CN110691593B (pt)
AU (1) AU2018277981B2 (pt)
BR (1) BR112019024881A2 (pt)
CA (1) CA3067455C (pt)
IL (1) IL270910B2 (pt)
MX (1) MX2019014302A (pt)
NZ (1) NZ759647A (pt)
RU (1) RU2728717C1 (pt)
SG (1) SG11201911515QA (pt)
WO (1) WO2018221730A1 (pt)
ZA (1) ZA201907974B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024851A2 (pt) 2017-06-02 2020-06-09 Fujifilm Toyama Chemical Co Ltd agente para evitar ou tratar atrofia cerebral
EP3636262A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
RU2019138538A (ru) 2017-06-02 2021-07-09 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. СРЕДСТВО ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА АМИЛОИДНОГО β-БЕЛКА
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218345T1 (de) * 1994-08-05 2002-06-15 Suntory Ltd Arzneimittel gegen spinocerebellare degeneration
JP2001514024A (ja) 1997-09-05 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
PL215264B1 (pl) 2001-10-19 2013-11-29 Toyama Chemical Co Ltd Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
KR101096528B1 (ko) 2003-04-17 2011-12-20 토야마 케미칼 컴퍼니 리미티드 알킬에테르 유도체 또는 그 염을 함유하는 망막신경질환의예방·치료제
ES2727452T3 (es) * 2004-09-09 2019-10-16 Shionogi & Co Composición farmacéutica para tratar ataxia, atrofia multisistémica o trastornos del equilibrio
TWI350754B (en) * 2004-09-09 2011-10-21 Shionogi & Co A pharmaceutical composition for treating spinocerebellar ataxia
WO2007125913A1 (ja) 2006-04-26 2007-11-08 Toyama Chemical Co., Ltd. アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
EP2265578B1 (en) * 2008-03-04 2015-09-16 Vernalis (R&D) Ltd. Azetidine derivatives
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
PL2818165T3 (pl) 2012-02-22 2019-09-30 Fujifilm Toyama Chemical Co., Ltd. Stała kompozycja farmaceutyczna zawierająca 1-(3-(2-(1-benzotiofen-5-ylo)etoksy)propylo)-azetydyn-3-ol albo jego sól
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
CN104703981B (zh) * 2012-10-01 2017-03-29 霍夫曼-拉罗奇有限公司 作为cns活性药剂的苯并咪唑类化合物
SG10201907035TA (en) * 2014-01-31 2019-09-27 Fujifilm Toyama Chemical Co Ltd Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
JP6165323B2 (ja) 2014-04-25 2017-07-19 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
US20180022748A1 (en) 2015-02-02 2018-01-25 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
US10238632B2 (en) 2015-06-11 2019-03-26 Fujifilm Toyama Chemical Co., Ltd. Sigma receptor-binding agent
US11304928B2 (en) 2015-12-25 2022-04-19 Fujifilm Toyama Chemical Co., Ltd. Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
RU2019138538A (ru) 2017-06-02 2021-07-09 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. СРЕДСТВО ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА АМИЛОИДНОГО β-БЕЛКА
KR20220101001A (ko) 2017-06-02 2022-07-18 후지필름 도야마 케미컬 가부시키가이샤 타우병증 예방 또는 치료제
EP3636262A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
BR112019024851A2 (pt) * 2017-06-02 2020-06-09 Fujifilm Toyama Chemical Co Ltd agente para evitar ou tratar atrofia cerebral
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Also Published As

Publication number Publication date
IL270910B2 (en) 2024-03-01
RU2728717C1 (ru) 2020-07-30
AU2018277981A1 (en) 2019-12-19
MX2019014302A (es) 2022-07-05
US11660287B2 (en) 2023-05-30
JPWO2018221730A1 (ja) 2020-04-09
KR20190138696A (ko) 2019-12-13
WO2018221730A1 (ja) 2018-12-06
IL270910A (en) 2020-01-30
EP3632430A1 (en) 2020-04-08
CN110691593A (zh) 2020-01-14
IL270910B1 (en) 2023-11-01
JP7133547B2 (ja) 2022-09-08
US20200085787A1 (en) 2020-03-19
ZA201907974B (en) 2022-03-30
EP3632430A4 (en) 2020-06-10
CA3067455A1 (en) 2018-12-06
CN110691593B (zh) 2023-05-02
CA3067455C (en) 2021-11-23
NZ759647A (en) 2022-02-25
SG11201911515QA (en) 2020-01-30
AU2018277981B2 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
BR112019024881A2 (pt) Agente para evitar ou tratar ataxia espinocerebelar
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
BR112019024851A2 (pt) agente para evitar ou tratar atrofia cerebral
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BRPI1012219C1 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2015004644A (es) Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados.
MX2016011822A (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas.
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
BR112012018170B8 (pt) agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos
UY32045A (es) Compuesto amida
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
AR101740A1 (es) Terapia de combinación y composiciones
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
BR112019024878A2 (pt) Agente para prevenção ou tratamento de tauopatia
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CL2011002650A1 (es) Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson.
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
BRPI0916885B8 (pt) composição farmacêutica
BR112019004684A2 (pt) combinação de agonistas de fxr

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]